Q-omics provides the consensus-scored TNKS2 profile across patient tissues and cancer cell-line models. TNKS2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNKS2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TNKS2 RNA expression shows 20,703 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TNKS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNKS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNKS2 survival associations across molecular data types. TNKS2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNKS2 RNA expression–survival associations across cancer types. High TNKS2 expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, UCS, LGG and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TNKS2 RNA expression.
This table summarizes TNKS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TNKS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNKS2 shows lower tumor expression in THCA and KICH and higher tumor expression in CHOL, LIHC, HNSC and BLCA. The THCA box plot shows higher TNKS2 RNA expression in normal versus tumor tissue (log2 FC = −0.449, t-test p < 0.001).
This table shows molecular features associated with TNKS2 in patient tissues and cancer cell lines. In patient samples, TNKS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNKS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
